Sign in Subscribe
Biochemistry

Researchers Establish Drug-Resistant Oral Squamous Cell Carcinoma Models

Strategic Insights

— 1 min read

Researchers from the Peking University School and Hospital of Stomatology in Beijing, People's Republic of China, have developed new data in the field of Oncology, specifically in the area of oral squamous cell carcinoma (OSCC). OSCC accounts for 90% of oral tumors and poses a significant challenge due to its anatomical location and limited treatment options. The study aimed to create drug-resistant OSCC models using patient-derived xenograft (PDX) models, which are essential for precision medicine.

Key Takeaways:

  • The study established drug-resistant OSCC PDX models by transplating human OSCC tissues into immunodeficient mice and passing them through serial treatments with cisplatin, cetuximab, GSK690693, and rapamycin.
  • The researchers observed that successive passaging accelerates tumor growth, and first-generation treatments showed universal sensitivity.
  • At P2, cisplatin-cetuximab and rapamycin groups remained sensitive, whereas GSK690693 efficacy declined, leading to the establishment of a resistant model.
  • The study suggests that sequential passaging and drug exposure in PDX models can recapitulate clinical tumor evolution, enabling the development of drug-resistant OSCC models.
  • The findings of this study can provide methodological insights for precision therapy of OSCC.
  • The research included a team of authors from the Peking University School and Hospital of Stomatology, including Hao Liu, Chuanni Feng, Yalan Lu, Yanfeng Xu, Xinghan Wu, Jinlong Wang, Chuan Qin, Binbin Li, and Yanhong Li.

Statistics:

  • 90% of oral tumors are oral squamous cell carcinoma (OSCC).
  • The study aimed to establish drug-resistant OSCC PDX models.
  • 40-80 mm tumor volume was reached at passaging (P2) in mice.
  • GSK690693 showed a decline in efficacy at P2, while cisplatin-cetuximab and rapamycin groups remained sensitive.
  • The resistant model was established first using GSK690693, with resistant models of other treatment groups established according to similar protocols.

Sources:

  • NewsRx. Data on Oral Squamous Cell Carcinoma Detailed by Researchers at Peking University School and Hospital of Stomatology (Establishment of a patient-derived drug-resistant oral squamous cell carcinoma animal model). Immunotherapy Weekly. September 17, 2025; p 1350.

Read more